Advertisement
Journal Home
Search for

Volume 54, Issue 6, Pages 697-704 (November 2009)


View previous. 6 of 11 View next.

Characteristics of Orbital Multiple Myeloma: A Case Report and Literature Review

Cat N. Burkat, MDCorresponding Author Informationemail address, Jeremy J. Van Buren, MD, PhD, Mark J. Lucarelli, MD

published online 26 August 2009.

Abstract 

Multiple myeloma is a plasma cell malignancy that destroys skeletal, renal, and neurological function. Orbital involvement is rare, but has been considered an initial presentation for the malignancy. Furthermore, an association between the subtype of multiple myeloma and the likelihood of orbital infiltration has been suggested. We present a case of an orbital mass that was a recurrence of multiple myeloma. A literature search was performed to evaluate the presentation characteristics of orbital multiple myeloma, plasmacytoma and primary (or solitary) extramedullary plasmacytoma. Past reports were analyzed for age, sex, symptoms at presentation, time from symptom onset to presentation, prior diagnosis before presentation for orbital symptoms, radiological characteristics, immunoglobulin subtype, and survival times. Less than half of published cases had orbital multiple myeloma as the primary presentation. Proptosis is the major presenting sign of orbital multiple myeloma, and radiological evaluation shows that the majority of masses originate in the superotemporal quadrant. The dominant immunoglobulin subtype was IgG.

Stefan Seregard and Milton Boniuk, Editors

Oculoplastics Service, Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin, USA

Corresponding Author InformationReprint address: Dr. Cat Nguyen Burkat, Oculoplastics Service, Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin 53792-3284, USA.

 The authors reported no proprietary or commercial interest in any product mentioned or concept discussed in this article. Supported in part by an unrestricted grant from Research to Prevent Blindness Inc., NY, NY.

PII: S0039-6257(09)00117-9

doi:10.1016/j.survophthal.2009.04.012


View previous. 6 of 11 View next.

Advertisement